Gastric cancer (GC) is the fourth leading cause of death worldwide, with over 1 million cases diagnosed annually. *Helicobacter pylori* is the primary risk factor, responsible for 78% of cases. Other risk factors include diet, lifestyle, and genetic mutations. The PI3K/AKT/mTOR and MAPK signaling pathways are key regulators in GC development, promoting cell survival, proliferation, and metastasis. Inhibitors targeting these pathways have shown promising results in clinical trials and in vitro studies. The review covers the incidence and risk factors of GC, the dysregulation of the PI3K/AKT/mTOR and MAPK pathways, and the specific inhibitors used in treatment.Gastric cancer (GC) is the fourth leading cause of death worldwide, with over 1 million cases diagnosed annually. *Helicobacter pylori* is the primary risk factor, responsible for 78% of cases. Other risk factors include diet, lifestyle, and genetic mutations. The PI3K/AKT/mTOR and MAPK signaling pathways are key regulators in GC development, promoting cell survival, proliferation, and metastasis. Inhibitors targeting these pathways have shown promising results in clinical trials and in vitro studies. The review covers the incidence and risk factors of GC, the dysregulation of the PI3K/AKT/mTOR and MAPK pathways, and the specific inhibitors used in treatment.